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Determination of related impurities in glimepiride tablets by the 
HPLC method
Glimepiride is one of the modern and effective drugs that counteract diabetes mellitus type 2. Like other drugs 
glimepiride must comply with quality standards set by relevant government departments.
Aim. To determine the content of related impurities in glimepiride tablets in order to assess the drug quality.
Materials and methods. The study was performed by the reversed-phase HPLC with a spectrophotometric de-
tector in the isocratic mode, in the UV-region of the spectrum. To determine impurities the method of comparison with 
the solution having the known concentration of impurities and the active substance was used.
Results and discussion. It has been shown that the drug contains ≤ 0.18 % of identified and unidentified impurities. 
Conclusions. The purity of the drug complies with the requirements of normative documents.
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Визначення методом ВЕРХ вмісту супутніх домішок у таблетках глімепіриду 
Одним із сучасних і ефективних ліків, що протидіють діабету 2-го типу, є глімепірид. Як і інші лікарські засо-
би, глімепірид повинен відповідати стандартам якості, встановленим уповноваженими державними установами.
Мета роботи – здійснення контролю якості супутніх домішок таблеток глімепіриду. 
Матеріали та методи. Дослідження проводились методом обернено-фазової ВЕРХ на спектрофотометрич-
ному детекторі в ізократичному режимі з детектуванням в УФ-області спектра. Для визначення вмісту домішок 
був застосований метод порівняння з розчином, що має відому концентрацію домішок і основної речовини.
Результати та їх обговорення. Показано, що лікарський препарат містить ≤ 0,18 % ідентифікованих та 
неідентифікованих домішок. 
Висновки. За перевіреним показником таблетки глімепіриду відповідають вимогам нормативних документів. 
Ключові слова: глімепірид; таблетки; контроль якості; цукровий діабет 2-го типу; ВЕРХ; супутні домішки
Н. А. Савина, Н. Н. Очеретяна, В. Н. Брицун, Н. В. Останина
Определение методом ВЭЖХ содержания сопутствующих примесей в таблетках 
глимепирида 
Глимепирид – современное лекарство, эффективно противодействующее диабету 2-го типа. Как и другие 
лекарственные средства, глимепирид должен соответствовать стандартам качества, установленным уполно-
моченными государственными учреждениями.
Цель работы. Для оценки качества лекарства был проведен контроль содержания сопутствующих приме-
сей в таблетках глимепирида. 
Материалы и методы. Исследования осуществлялись методом обращенно-фазовой ВЭЖХ на спектро-
фотометрическом детекторе в изократическом режиме с детектированием в УФ-области спектра. Для установ-
ления содержания примесей использовался метод сравнения с раствором, содержащим известную концентра-
цию примесей и основного вещества.
Результаты и их обсуждение. Лекарственный препарат содержит ≤ 0,18 % идентифицированных и не-
идентифицированных примесей. 
Выводы. Показано, что по проверенному показателю таблетки глимепирида соответствуют требованиям 
нормативных документов. 
Ключевые слова: глимепирид; таблетки; контроль качества; сахарный диабет 2-го типа; ВЭЖХ; 
сопутствующие примеси
Diabetes is a chronic disease of the endocrine na-
ture. It is a disorder of all types of metabolism of the 
human body [1]. Diabetes is a heavy social and econo- 
mic burden, cause many complications and pathologies 
that reduce the efficiency and the life expectancy of the 
population of the average and preretirement age [2, 3].
Currently, more than 250 million people in the world 
have diabetes. The prevalence of diabetes in the popu-
lation is 3-4 %, and it reaches 10-16 % among middle-
aged adults in the Near East [1, 2].
There is a persistent trend of increasing morbidity, 
which has an epidemic character. It is believed that due 
to the aging population, the number of patients over the 
next two decades will double [3].
In Ukraine diabetes was diagnosed for 2.8 % of the 
population in 2014 [4]. Annually aproximately 100 000 
new cases of the disease are recorded. 
The state projects for reducing the diabetes negative 
impact exist in many countries. In particular, the state 
target program “Diabetes mellitus” was functioned in 
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Ukraine in 2009-2013 (CMU Resolution No. 877 from 
19.09.2009) [5]. 
An insufficient production of insulin by the pancreas 
is the cause of the pathogenic effect of diabetes type 1, 
whereas expressed insulin inactivation or destruction of 
insulin receptors on membranes of the body cells is ob-
served in the diabetes type 2. 
To control diabetes type 2 hypoglycemic agents – 
drugs that reduce blood glucose levels are used. They 
are sulfonylureas (glibenclamide, glimepiride, tolbutami- 
de, chlorpropamide), biguanides (metformin), thiazoli-
dinone derivatives (troglitazone, rosiglitazone), alpha-
glucosidase inhibitors (acarbose and miglitol), dipepti- 
dyl peptidase inhibitors (sitagliptin, vildagliptin), incre-
tins [6].
One of the modern and effective drug to control dia-
betes type 2 is glimepiride, which triggers the insulin 
production by the pancreas, increases the number of insu- 
lin-sensitive receptors and inhibits gluconeogenesis [7, 8].
All medicines in Ukraine must meet quality stan- 
dards, which are regulated by the State Pharmacopoeia 
of Ukraine, the documents of the State Expert Center of 
the MHP of Ukraine and the State Service of Ukraine 
on medicines and drug control. The quality control of 
medicines is carried out in the authorized analytical la- 
boratories, which have the necessary equipment and the 
staff of the qualified professionals, certified and accredi- 
ted in the relevant institutions [9]. 
Scheme 1 of the glimepiride synthesis based on the 
use of 5-dihydro-3-ethyl-4-methylpyrolin-2-one 1 as the 
starting reagent contains 5 stages [10].
Taking into account the multi-stage synthesis and 
possible deviations from the optimal storage conditions 
the substance and the finished dosage forms of glimepi- 
ride may contain compounds that are byproducts of for-
mation and partial decomposition of the active substance 
(related impurities). They are pollutants because their con-
tent is strictly limited and requires mandatory control.
The aim of this work is to study the content of related 
impurities in glimepiride by HPLC for compliance with 
the requirements of normative documents.
Materials and methods
For the tests glimepiride tablets of foreign produc-
tion were used.
The study was performed by the reversed-phase HPLC 
on an Agilent 1200 chromatograph with a spectrophoto-
metric detector in the isocratic mode, in the UV-region 
of the spectrum using an Inertsil CAS-3V column (with 
the length of 250 mm, the diameter of 4.6 mm, the par-
ticle size of 5 mm). The column temperature was 25 °C, 
the rate of the mobile phase – 1 ml/min, λ = 228 nm, the 
injection volume – 20 μl, the mobile phase – phosphate 
buffer: acetonitrile.
Sulfonamide solution: add 50 ml of methanol to 
39.92 mg of the sulfonamide standard in a 100.0 mL 
volumetric flask, shake to dissolve and dilute to the volu- 
me with the same solvent.
Carbamate solution: add 50 ml of methanol to 4.20 mg 
of the carbamate standard in a 100.0 ml volumetric flask, 
shake to dissolve and dilute to the volume with the same 
solvent.
Glimepiride solution: add 50 ml of methanol to 4.12 mg 
of the glimepiride standard in a 100.0 mL volumetric 
flask, shake to dissolve and dilute to the volume with 
the same solvent.
Reference solution for injections: pipette 2.0 ml of 
solutions of sulfonamide, carbamate, glimepiride each 
in a 200.0 mL volumetric flask and dilute to the volume 
with methanol. The concentrations of sulfonamide, car-
bamate, glimepiride are 3.992, 0.42 and 0.412 mg/ml, 
respectively.
Test solution of glimepiride: crush 20 tablets, weigh 
599.43 mg (equivalent to 10 mg of glimepiride), trans-
fer to a 25.0 ml volumetric flask. Add 20 ml of metha-
nol, shake to dissolve, dilute to the volume with the same 
solvent and filter.
Scheme 1
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The results of the chromatographic study of the refe- 
rence and test solutions are shown in Tab. 1 and 2, re-
spectively.
Statistical analysis of the results obtained and esti-
mated uncertainty were carried out in accordance with 
the pharmacopoeial requirements (SPhU and Ph. Eur.) 
[11, 12].
The chromatographic system suitability test corres- 
ponded to the requirements specified (the mean value of 
the symmetry factor for 5 parallel injections was within 
1.04-1.05; the relative standard deviation of peak areas 
of the reference solution was less than 2.0 %, and the 
number of theoretical plates was ≥ 5000).
Results and discussion
According to the data of the European Pharmaco-
poeia [12] the glimepiride substance can have not more 
than 0.9 % of impurities, in particular identified com-
pounds A-J (Scheme 2).
Compounds B (sulfonamide) and C (carbamate) are 
formed at the last stages of the glimepiride synthesis. 
They have similar solubility. These impurities are basic 
in the substance and medicines of glimepiride.
For glimepiride tablets under study the following re-
quirements were set by manufacturer: the content of re- 
lated impurities should be not more than 1.0 % (for sul-
fonamide and carbamate – not more than 0.6 and 0.1 %, 
respectively).
For the quantitative determination of impurities the 
method of comparison with the standard solution con-
taining the known concentration of impurities and the 
active substance was used The reference and test solu-
tions were injected, and peak areas on the chromato-
grams were integrated, after that the content of impuri-
ties was calculated. 
The test results are given in Tab. 1, 2. The chroma-
togram of the test solution of glimepiride is presented 
in Fig.
The content of sulfonamide (%) was calculated using 
the formula:
Сsulf = (Sinv / Sеt) × (msamp / 4) × (1 / mgl) × (Аv / D ) × Р,
where: Sinv – is the average peak area of sulfonamide on 
the chromatogram of the test solution; Sеt – is the average 
Table 1
The results of the chromatographic study of the standard solutions of sulfonamide, carbamate and glimepiride 
No.
Sulfonamide Carbamate Glimepirid
Retention time, min Peak area Retention time, min Peak area Retention time, min Peak area
1 6.483 337.485 8.971 32.004 34.083 27.770
2 6.467 337.697 8.952 32.427 34.138 27.496
3 6.479 339.370 8.963 32.210 34.020 27.655
Mean 6.476 338.184 8.962 32.214 34.080 27.640
RSD, % 0.13 0.31 0.11 0.66 0.17 0.50
Note: The peak resolution factor for sulfonamide and carbamate is 7.74-7.77.
 
Table 2 
The results of the chromatographic study  
of the test solution of glimepiride 













































RSD, % 0.42 0.05
Note: the symmetry coefficient of peaks on the 
chromatograms is 1.01-1.20.
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peak area of sulfonamide on the chromatogram of the 
standard solution; msamp – is the weight of the sulfon- 
amide standard (mg); mgl – is the weight of the gli- 
mepiride sample (599.43 mg); Аv – is the average 
weight of tablets (359.85 mg); D – is the labeled 
amount of glimepiride per tablet, Р – is the purity of 
the standard sample of sulfonamide (0.991). 
Calculation using digital data from Tab. 1, 2 and in-
formation from the experimental part shows that the sul- 
fonamide content is 0.12 %. 
The content of carbamate (%) was calculated using 
the formula:
Сcarb = (Sinv / Sеt) × (mst / 4) × (1 / msamp) × (Аv / D ) × Р,
where: Sinv – is the average peak area of carbamate on the chro-
matogram of the test solution; Sеt – is the average peak area 
of carbamate on the chromatogram of the standard solution; 
mst – is the weight of the carbamate sample (mg); msamp – is 
the weight of the glimepiride sample (599.43 mg); Аv – is 
Scheme 2
Fig. Chromatogram of the test solution of glimepiride
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the average weight of tablets (359.85 mg); D – is the labeled 
amount of glimepiride per tablet; Р – is the purity of the 
standard sample of carbamate (0.969). 
Calculation using data from Tab. 1, 2 and informa-
tion from the experimental part indicates that the carba-
mate content is 0.01 %.
Calculation of the content of unidentified impurities 
was performed using the formula:
Сun = (Sinv / Sgl) × (mst / 4) × (1 / msamp) × (Аv / D ) × Р,
where: Sinv – is the average peak area of the unidentified im-
purity on the chromatogram of the test solution; Sgl – is the 
average peak area of glimepiride on the chromatogram of 
the standard solution; mst – is the weight of the glimepiride 
standard (mg); msamp – is the weight of the glimepiride sample 
(599.43 mg); Аv – is the average weight of tablets (359.85 mg); 
D – is the labeled amount of glimepiride per tablet; Р – is the 
purity of the standard sample of glimepiride (0.995). 
Calculation using data from the experimental part 
and Tab. 1.2 shows that the content of unidentified im-
purities 1-3 is 0.01, 0.03 and 0.01 % (0.05 % of the total 
amount), respectively.
The total amount of impurities was calculated by the 
formula:
% imp = Сsulf + Сcarb + Сunident.
The total content of identified and unidentified im-
purities 1-3 is 0.18 %. This is significantly less than the 
permitted value of 1.0 %.
CONCLUSIONS
Testing of glimepiride (tablets) on the content of re-
lated impurities by the HPLC method has shown that the 
drug meets the requirements of normative documents 
and is safe for consumers.
Conﬂicts of Interest: authors have no conflict of 
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